Figure 5 | Scientific Reports

Figure 5

From: A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept

Figure 5

Measurement of SARS-CoV-2 S pseudotyped VP-neutralization activity from human samples. (A) Pre-pandemic sera. (B) COVID-19 convalescent sera. (C) BNT162b2 vaccinated sera. Orange: sample obtained on average 19 days [range: 13–22] after the first vaccine dose, purple: sample obtained on average 26 days [range: 22–29] after the 2nd vaccine dose. (D) Calculations of assay sensitivity, specificity and accuracy using neutralization results at 1:20 sera dilutions. The dotted line represents an arbitrary 30% neutralization cutoff for titers estimation. p < 0.0001 (****).

Back to article page